Uric acid: Its relationship to renal hemodynamics and the renal renin-angiotensin system

Current Hypertension Reports

Volumn 8, Issue 2, 2006, Pages 120-124

  Zhou, Xiaoyan ^b   Matavelli, Luis ^b   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ARGININE METHYL ESTER; BENZIODARONE; CALCIUM ANTAGONIST; ENALAPRIL; EPLERENONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OXONIC ACID; URIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; ESSENTIAL HYPERTENSION; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; NEPHROSCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY TOXEMIA; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; URIC ACID BLOOD LEVEL;

HUMANS; KIDNEY; KIDNEY DISEASES; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; URIC ACID;

EID: 33744500756     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0007-x     Document Type: Article

References (47)

1. Stanton JR, Freis ED: Serum uric acid concentration in essential hypertension. Proc Soc Exp Bio Med 1947, 66:193-194.
2. Rieselbach RE, Steele TH: Influence of the kidney upon urate homeostasis in health and disease. Am J Med 1974, 56:665-675.
3. Steele TH: Control of uric acid excretion. N Engl J Med 1971, 284:1193-1196.
4. Cannon PJ, Stason WB, Demartini FE, et al.: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966, 275:457-464.
5. Breckenridge A: Hypertension and hyperuricaemia. Lancet 1966, 1:15-18.
6. Saggiani F, Pilati S, Targher G, et al.: Serum uric acid and related factors in 500 hospitalized subjects. Metabolism 1996, 45:1557-1561.
7. Frohlich ED: Uric acid: a risk factor for coronary heart disease. JAMA 1993, 21, 270:378-379.
8. Verdecchia P, Schillaci G, Reboldi G, et al.: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000, 36:1072-1078.
9. Lam C, Lim KH, Kang DH, Karumanchi SA: Uric acid and preeclampsia. Semin Nephrol 2005, 25:56-60.
10. Facchini F, Chen YD, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266:3008-3011.
11. Lee J, Sparrow D, Vokonas PS, et al.: Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol 1995, 142:288-294.
12. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al.: Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005, 16:791-799.
13. Ferris TF, Gorden P: Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 1968, 44:359-365.
14. Messerli FH, Frohlich ED, Dreslinski GR, et al.: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980, 93:817-821.
15. Kobrin I, Frohlich ED, Ventura HO, Messerli FH: Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med 1986, 146:272-276.
16. Nunez BD, Frohlich ED, Garavaglia GE, et al.: Serum uric acid in renovascular hypertension: reduction following surgical correction. Am J Med Sci 1987, 294:419-422.
17. Sesoko S, Pegram BL, Willis GW, Frohlich ED: DOCA-salt induced malignant hypertension in spontaneously hypertensive rats. J Hypertens 1984, 2:49-54.
18. Ono H, Ono Y, Frohlich ED: ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996, 27:176-183.
19. Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998, 31:795-801.
20. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N-nitro-L-arginine methyl ester/spontaneously hypertensive rats. Hypertension 2001, 37:1262-1267.
21. Zhou X, Ono H, Ono Y, Frohlich ED: N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an L-NAME/ SHR model. J Hypertens 2002, 20:993-1000.
22. Zhou X, Ono H, Ono Y, Frohlich ED: Renoprotective effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol 2003, 23:214-221.
23. Zhou X, Ono H, Ono Y, Frohlich ED: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004, 24:242-249.
24. Ono H, Ono Y, Frohlich ED: Nitric oxide synthesis inhibition in spontaneously hypertension rats: systemic, renal, and glomerular hemodynamics. Hypertension 1995, 26:249-255.
25. Frohlich ED: Arthur C. Corcoran Memorial Lecture: influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997, 29:188-193.
26. Zhou X, Frohlich ED: Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitric oxide suppressed rats. Am J Nephrol 2005, 25:138-152.
27. Johnson RJ, Kang DH, Feig D, et al.: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41:1183-1190.
28. Mazzali M, Hughes J, Kim YG, et al.: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101-1106.
29. Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al.: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002, 283:F1105-F1110.
30. Mazzali M, Kanellis J, Han L, et al.: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991-F997.
31. Nakagawa T, Mazzali M, Kang DH, et al.: Hyperuricemia causes glomerular hypertrophy In the rat. Am J Nephrol 2003, 23:2-7.
32. Kang DH, Nakagawa T, Feng L, et al.: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002, 13:2888-2897.
33. Sanchez-Lozada LG, Tapia E, Santamaria J, et al.: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005, 67:237-247.
34. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH: Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005, 45:18-20.
35. Feig DI, Johnson RJ: Hyperuricemia in childhood primary hypertension. Hypertension 2003, 42:247-252.
36. Alper AB Jr, Chen W, Yau L, et al.: Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005, 45:34-38.
37. Johnson RJ, Kivlighn SD, Kim YG, et al.: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999, 33:225-234.
38. Syrjanen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000, 15:34-42.
39. Ohno I, Hosoya T, Gomi H, et al.: Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001, 87:333-339.
40. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
41. Hoieggen A, Alderman MH, Kjeldsen SE, et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. LIFE Study Group. Kidney Int 2004, 65:1041-1049.
42. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7-13.
43. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991, 266:8604-8608.
44. Netea MG, Kullberg BJ, Blok WL, et al.: The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997, 89:577-582.
45. Kanellis J, Watanabe S, Li JH, et al.: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287-1293.
46. Khosla UM, Zharikov S, Finch JL, et al.: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739-1742.
47. Perlstein TS, Gumieniak O, Hopkins PN, et al.: Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004, 66:1465-1470.